Aspira Women's Health Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Aspira Women's Health de winst en omzet met respectievelijk 15.4% en 52.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 30.5% per jaar.

Belangrijke informatie

15.4%

Groei van de winst

30.5%

Groei van de winst per aandeel

Medical Equipment winstgroei	14.7%
Inkomstengroei	52.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	30 Oct 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:CUL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	33	-10	N/A	N/A	3
12/31/2025	20	-15	N/A	N/A	4
12/31/2024	10	-16	N/A	N/A	3
6/30/2024	9	-16	-15	-15	N/A
3/31/2024	9	-15	-15	-15	N/A
12/31/2023	9	-17	-16	-16	N/A
9/30/2023	9	-18	-20	-20	N/A
6/30/2023	9	-21	-24	-24	N/A
3/31/2023	9	-27	-27	-27	N/A
12/31/2022	8	-30	-31	-31	N/A
9/30/2022	8	-34	-32	-32	N/A
6/30/2022	7	-36	-32	-32	N/A
3/31/2022	7	-35	-33	-32	N/A
12/31/2021	7	-32	-28	-27	N/A
9/30/2021	6	-29	-25	-25	N/A
6/30/2021	6	-23	-20	-20	N/A
3/31/2021	5	-20	-17	-16	N/A
12/31/2020	5	-18	-15	-15	N/A
9/30/2020	5	-15	-13	-13	N/A
6/30/2020	5	-15	-13	-13	N/A
3/31/2020	5	-15	-13	-13	N/A
12/31/2019	5	-15	-13	-13	N/A
9/30/2019	4	-15	-13	-12	N/A
6/30/2019	4	-14	-11	-11	N/A
3/31/2019	3	-12	-10	-10	N/A
12/31/2018	3	-11	-9	-9	N/A
9/30/2018	3	-12	-9	-9	N/A
6/30/2018	3	-12	-9	-9	N/A
3/31/2018	3	-12	N/A	-8	N/A
12/31/2017	3	-11	N/A	-8	N/A
9/30/2017	3	-11	N/A	-9	N/A
6/30/2017	3	-11	N/A	-10	N/A
3/31/2017	3	-13	N/A	-11	N/A
12/31/2016	3	-15	N/A	-14	N/A
9/30/2016	2	-17	N/A	-16	N/A
6/30/2016	2	-19	N/A	-17	N/A
3/31/2016	2	-20	N/A	-19	N/A
12/31/2015	2	-19	N/A	-18	N/A
9/30/2015	3	-18	N/A	-18	N/A
6/30/2015	3	-19	N/A	-19	N/A
3/31/2015	3	-19	N/A	-18	N/A
12/31/2014	3	-19	N/A	-17	N/A
9/30/2014	3	-17	N/A	-15	N/A
6/30/2014	3	-14	N/A	-12	N/A
3/31/2014	3	-10	N/A	-10	N/A
12/31/2013	3	-9	N/A	-8	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CUL de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CUL de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CUL de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CUL ( 52.6% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van CUL ( 52.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CUL naar verwachting over 3 jaar hoog zal zijn

Aspira Women's Health Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Aspira Women's Health Inc. to Report Nine Months, 2024 Results on Nov 14, 2024

Aspira Women's Health Inc. Announces Its Selection Receive $10 Million Award from Advanced Research Projects Agency for Health’s Sprint for Women's Health

Aspira Women's Health Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Second quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 2Q 2023)

Aspira Women's Health Inc. Appoints John Kallassy as Interim Chief Financial Officer, Effective August 15, 2024

New major risk - Shareholder dilution

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $4.45 million.

Aspira Women's Health Inc. to Report Q2, 2024 Results on Aug 12, 2024

Aspira Women’s Health Inc Appoints John Ragard to Its Board of Directors

New major risk - Shareholder dilution

Aspira Women's Health Inc. announced that it has received $1.910249 million in funding

Aspira Women’s Health Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)

Aspira Women's Health Inc. announced that it expects to receive $1.935051 million in funding

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.73 loss in 1Q 2023)

Aspira Women's Health Inc. to Report Q1, 2024 Results on May 15, 2024

Aspira Women's Health Inc. Enhances Its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of Ovawatch

Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024

Aspira Women's Health Inc., Annual General Meeting, May 13, 2024

Full year 2023 earnings released: US$1.81 loss per share (vs US$3.85 loss in FY 2022)

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Inc. to Report Q4, 2023 Results on Mar 28, 2024

High number of new and inexperienced directors

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $5.50031 million.

Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors

Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Aspira Women's Health Inc. to Report Q3, 2023 Results on Nov 13, 2023

Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

Aspira Women's Health Establishes A New Clinical Advisory Board

Aspira Women’s Health Regains Nasdaq Compliance

Aspira Women’s Health Announces Executive Changes

Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations

Aspira Women’S Health Inc. Announces Resignation of Ryan Phan as Chief Scientific and Operating Officer, Effective September 15, 2023

Aspira Women's Health Inc. to Report Q2, 2023 Results on Aug 14, 2023

Aspira Women’s Health Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors, Member of Nominating and Corporate Governance Committee

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors

Aspira Women's Health Inc. Announces Chief Financial Officer Changes, Effective June 15, 2023

First quarter 2023 earnings released: US$0.73 loss per share (vs US$1.24 loss in 1Q 2022)

Aspira Women's Health Inc. Appoints Three New Members to Its Board of Directors

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.28 loss in FY 2021)

Aspira Women’s Health Inc. Announces Publication of Real-World Data Validating Use of OvaWatch for Management of Adnexal Masses

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Receives A Written Notice from Nasdaq

Aspira Women's Health Inc. Announces the Commercial Launch of OvaWatch

Third quarter 2022 earnings released: US$0.039 loss per share (vs US$0.087 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.039 loss per share (vs US$0.087 loss in 3Q 2021)

Aspira Women's Health Inc. to Report Q3, 2022 Results on Nov 10, 2022

Aspira Women's Health Inc. Announces Publication of Its Second-Generation Multivariate Index Assay, Overa®, in the Detection of Cancer in Filipino Women

Aspira Women's Health Inc. has completed a Follow-on Equity Offering.

Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.063 loss in 2Q 2021)

Aspira Women's Health Inc. to Report Q2, 2022 Results on Aug 10, 2022

Aspira Women's Health Inc. Announces Board Appointments

Aspira Women’s Health Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

President recently bought €72k worth of stock

First quarter 2022 earnings released: US$0.083 loss per share (vs US$0.054 loss in 1Q 2021)

Aspira Women's Health Inc. Appoints Ryan Phan, Ph.D. as Chief Operating and Scientific Officer

Aspira Women's Health Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

Aspira Women's Health Inc. Appoints Valerie B. Palmieri as Its Executive Chairperson

Aspira Women’S Health Announces Appointment of Celeste Fralick to Its Board of Directors

Aspira Women's Health Inc. Appoints Nicole Sandford as Chief Executive Officer, Effective March 1, 2022

Aspira Women’s Health, Inc. Name Mr. Michael Newton as Head of Sales and Marketing

Third quarter 2021 earnings released: US$0.087 loss per share (vs US$0.042 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.063 loss per share (vs US$0.039 loss in 2Q 2020)

Aspira Women's Health Inc.(NasdaqCM:AWH) dropped from Russell 3000E Value Index

Independent Director David Schreiber has left the company

Aspira Women's Health Inc. Initiates Prospective Clinical Study for Benign Risk Monitoring and High Risk Early Ovarian Cancer Detection with Northwell Health®

Full year 2020 earnings released: US$0.18 loss per share (vs US$0.18 loss in FY 2019)

Aspira Women's Health Inc. to Report Q4, 2020 Results on Mar 25, 2021

Aspira Women's Health Inc. Appoints Nicole Sandford as a Director and Audit Committee of the Board

Insider recently bought €1.1m worth of stock

Aspira Women's Health Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

New 90-day high: €4.28